Pharmacy review for VIC TAC claims
Optimise medication management in Transport Accident Commission claims with specialist pharmacy review
Published: 3 April 2026 | Updated: 3 April 2026
Overview of Victoria's Transport Accident Commission and medication management
Victoria's Compulsory Third Party (CTP) motor accident scheme is administered by the Transport Accident Commission (TAC) under the Transport Accident Act 1986. The TAC is a government-run scheme with distinctive features, including no-fault liability and ongoing benefit provision for seriously injured claimants. As a TAC insurer managing claims, your obligation to provide appropriate, evidence-based medical management is central to claim sustainability and supporting claimant recovery.
Motor accident claims managed through TAC often involve complex injuries with potential for longer-term management and benefit provision. Medication management in TAC claims must balance acute pain management with the reality of longer-term impairment and disability. A specialist pharmacy review identifies medication-related risks and delivers practical recommendations aligned with TAC legislative expectations and rehabilitation principles.
Transport Accident Act and TAC framework for medication management
Legislative requirements and TAC expectations
The Transport Accident Act 1986 (Victoria) establishes the TAC scheme and places responsibility on TAC and treating practitioners to manage claimants' injuries appropriately. While pharmacy reviews are not explicitly mandated, they form part of the expectation that all medical treatment be reasonable, necessary, and evidence-based. TAC guidance emphasises coordinated care, rehabilitation focused on maximising claimant function, and evidence-based treatment pathways.
TAC requirement: Under the Transport Accident Act 1986, all medical treatment must be reasonable and necessary. A pharmacy review demonstrates your commitment to ensuring all medications meet this standard and support the claimant's recovery and long-term functional outcomes aligned with TAC principles.
TAC's serious injury focus and long-term management
TAC provides ongoing benefits and management for seriously injured claimants. This long-term perspective means that medication management in TAC claims must consider not just acute recovery but also sustainable long-term management that supports maximum function and quality of life. A pharmacy review that assesses long-term medication sustainability is particularly valuable in TAC contexts.
Why pharmacy review is essential in Victoria's TAC motor accident claims
Victoria's motor accident population includes significant serious injuries managed long-term through TAC. The long-term nature of TAC claims creates specific medication management challenges:
- Long-term opioid therapy for chronic pain without regular reassessment of continued necessity
- Multiple medications prescribed across different specialists without centralised oversight
- Medication side effects contributing to loss of function or preventing participation in rehabilitation
- Benzodiazepine dependence developing over long-term management periods
- Cost implications of long-term medication management affecting claim sustainability
A specialist pharmacy review delivers:
- Comprehensive medication audit aligned with current evidence and TAC expectations
- Risk assessment for interactions, adverse effects, and long-term dependence potential
- Clear recommendations for medication optimisation, deprescribing, or sustainable long-term regimen
- Implementation guidance supporting TAC rehabilitation and recovery objectives
- Enhanced alignment between medications and long-term functional capacity and quality of life
TAC claim pathway and optimal pharmacy review timing
The best timing for a pharmacy review in a TAC claim depends on injury severity, claim maturity, and recovery trajectory:
| Recovery phase | Medication profile | Pharmacy review indication |
|---|---|---|
| Acute injury (0-6 weeks) | Acute pain management; short-term anti-inflammatory and symptom control agents | Usually not required; acute symptom management is appropriate |
| Early recovery (6-16 weeks) | Transition from acute to ongoing management; potential medication escalation; rehabilitation commenced | Recommended if opioid escalation occurs or medications impede rehabilitation participation |
| Ongoing management (4-12 months) | Stable medication regimen; long-term polypharmacy established; serious injury status confirmed | Highly recommended to ensure long-term medication regimen is optimised and sustainable |
| Long-term support phase (12+ months) | Established long-term medications; chronic pain management; long-term disability management | Valuable for periodic reassessment to ensure long-term regimen remains optimal and supports quality of life |
Victoria and TAC-specific medication management considerations
No-fault scheme and serious injury focus
TAC operates as a no-fault scheme with substantial ongoing benefits for seriously injured claimants. This means medication management decisions have long-term implications. A pharmacy review should consider not just acute recovery but long-term sustainable medication management that supports ongoing function, participation, and quality of life.
TAC treating networks and integrated care
TAC has established treating networks and integrated care coordination structures. A pharmacy reviewer familiar with TAC networks and care pathways ensures recommendations are practical and aligned with TAC's integrated rehabilitation approach.
Long-term opioid management in TAC
Long-term opioid therapy is common in TAC seriously injured claims. A pharmacy review should explicitly assess whether long-term opioid regimens remain evidence-based, whether dose escalation is justified, and whether deprescribing or alternative approaches might improve long-term functional outcomes and quality of life.
Conducting a pharmacy review referral in TAC motor accident claims
Step 1: Identify referral triggers
Refer for a review when: the claim is transitioning from acute to ongoing management phase, serious injury status is confirmed, long-term medication regimen is being established, opioid or benzodiazepine escalation is occurring, or periodic reassessment of long-term medication sustainability is needed.
Step 2: Obtain claimant consent
Discuss the review with the claimant, framing it as an opportunity to ensure their long-term medication regimen is optimised to support their recovery and quality of life. Emphasise that recommendations will be shared with their treating doctor, and the doctor makes the final decision about implementation.
Step 3: Compile comprehensive motor accident documentation
Provide the reviewer with injury details and ongoing functional status, complete medication list with dosages and durations, pre-accident comorbidities or medications, current pain and functional status, psychological status and any mental health treatment, and long-term functional and quality of life goals.
Step 4: Facilitate treating practitioner communication
After the review, enable communication between the reviewer and the treating doctor. In TAC seriously injured claims, this is critical as the medication regimen may span many years. Building agreement around sustainable medication strategy significantly improves implementation and long-term outcomes.
Step 5: Monitor and support long-term management
After implementation, track the claimant's ongoing response to medication changes. Monitor for adverse effects, functional status, quality of life, participation in rehabilitation, and overall health outcomes. Support periodic reassessment to ensure the medication regimen continues to serve the claimant's long-term needs.
Evidence-based medication principles for TAC motor accident claims
Long-term pain management approach
In TAC seriously injured claims, long-term pain management requires balancing symptom control with functional capacity and quality of life. Current evidence favours multimodal approaches combining non-pharmacological strategies (exercise, psychology, lifestyle) with targeted pharmacotherapy. A pharmacy review should assess whether long-term opioid or benzodiazepine regimens remain justified or whether alternatives might improve long-term outcomes.
Long-term mental health medication management
TAC claimants with serious injury frequently experience depression, anxiety, or post-traumatic stress. Long-term psychotropic medication must be coordinated with pain management and reassessed periodically to ensure it continues to serve the claimant's mental health needs without creating harmful interactions or side effects.
Deprescribing and medication rationalisation in long-term claims
As TAC claimants progress through long-term management, some medications introduced in acute phases may no longer be necessary. A pharmacy review identifies opportunities for safe deprescribing that can improve quality of life and reduce medication-related risks without compromising management of ongoing injury-related symptoms.
Common medication scenarios in TAC motor accident claims
Serious musculoskeletal injury with long-term opioid therapy
TAC seriously injured claimants with severe musculoskeletal damage often receive long-term opioid therapy. A pharmacy review assesses whether the regimen remains evidence-based, whether escalation over time is justified by worsening symptoms or declining function, and whether long-term opioid sustainability aligns with quality of life goals.
Traumatic brain injury with polypharmacy for cognitive and behavioural management
TAC claimants with serious brain injury often require multiple medications for cognitive, behavioural, and mood management. A comprehensive pharmacy review assesses the entire regimen, looking for interactions, opportunities for simplification, and alignment with neurological and psychological recovery goals.
Spinal injury with long-term pain and psychological comorbidity
TAC claimants with serious spinal injuries often have complex polypharmacy for pain, spasticity, mood, and anxiety management. A pharmacy review ensures all medications are appropriately indicated, at evidence-based doses, and coordinated to support long-term functional capacity and psychological wellbeing.
Measuring pharmacy review outcomes in TAC motor accident claims
Track these metrics to demonstrate the value of pharmacy review in your TAC claims:
- Long-term medication sustainability: Percentage of claimants maintained on stable, evidence-based long-term regimen
- Deprescribing success: Percentage of claimants with medications safely ceased without relapse or deterioration
- Functional outcomes: Participation in rehabilitation; independence level; work or vocational engagement
- Quality of life: Self-reported health status; life satisfaction; participation in community activities
- Adverse event reduction: Medication-related complications avoided; hospitalisations prevented
Key resources for TAC medication management
These resources support medication management decisions in TAC motor accident claims:
- Transport Accident Commission (TAC): https://www.tac.vic.gov.au - Guidance on claim management and medical treatment standards
- Therapeutic Guidelines: Evidence-based prescribing recommendations used across Australia
- PBS (Pharmaceutical Benefits Scheme): Reference for medication eligibility and restrictions
- Victoria Health Services: Clinical guidance and health service information
Optimise long-term medication management for your TAC seriously injured claimants
IMM delivers specialised pharmacy reviews tailored to TAC motor accident claims. Our pharmacists work collaboratively with TAC teams, treating practitioners, and claimants to ensure long-term medication regimens support functional recovery, participation, and quality of life.
Request a Medication Review
